Details of the Drug

General Information of Drug (ID: DMSC4A7)

Drug Name

Indomethacin

Synonyms

Aconip; Amuno; Arthrexin; Artracin; Artrinovo; Artrivia; Bonidin; Bonidon; Catlep; Confortid; Dolcidium; Dolovin; Durametacin; Elmetacin; Hicin; IMN; Idomethine; Imbrilon; Inacid; Indacin; Indameth; Indmethacine; Indocid; Indocin; Indomecol; Indomed; Indomee; Indometacin; Indometacina; Indometacine; Indometacinum; Indometacyna; Indomethacine; Indomethacinum; Indomethancin; Indomethazine; Indomethegan; Indomethine; Indometicina; Indomo; Indomod; Indoptic; Indoptol; Indorektal; Indoxen; Inflazon; Infrocin; Lausit; Liometacen; Metacen; Metartril; Methazine; Metindol; Mezolin; Miametan; Mikametan; Mobilan; Novomethacin; Reumacide; Sadoreum; Tannex; Vonum; Bonidon Gel; DESMETHYL INDOMETHACIN; Dolcidium PL;Flexin continus; Indocid Pda; Indocid Sr; Indocin Sr; Indolar SR; Indometacyna [Polish]; Indometicina [Spanish]; Inteban sp; Rhemacin LA; Rheumacin LA; I 7378; IN1454; Indomet 140; Aconip (TN); Apo-Indomethacin; Chibro-amuno; Chrono-indicid; Chrono-indocid; Indo-Lemmon; Indo-Spray; Indo-phlogont; Indo-rectolmin; Indo-tablinen; Indocid (TN); Indocid (pharmaceutical); Indocin (TN); Indocin I.V; Indometacina [INN-Spanish]; Indometacine [INN-French]; Indometacinum [INN-Latin]; Indomethacin (USP); Indomethacin [USAN:BAN]; Novo-Methacin; Indochron E-R (TN); Indocin I.V.; Indocin-SR (TN); Indometacin (JP15/INN); Indomethacin & MAP-30; Indomethacin, Indochron E-R, Indocin-SR, Indocid, Indocin, Indomethacin

Indication

Disease Entry	ICD 11	Status	REF
Rheumatoid arthritis	FA20	Approved	[1]

Therapeutic Class

Antiinflammatory Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

357.8

Topological Polar Surface Area (xlogp)

4.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Bioavailability: 99% of drug becomes completely available to its intended biological destination(s) [3]
Clearance: The drug present in the plasma can be removed from the body at the rate of 1.3 mL/min/kg [4]
Elimination: 15% of drug is excreted from urine in the unchanged form [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.4 hours [4]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 7.985 micromolar/kg/day [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.01% [4]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.096 L/kg [4]
Water Solubility: The ability of drug to dissolve in water is measured as 0.0025 mg/mL [2]

Chemical Identifiers

Formula: C19H16ClNO4
IUPAC Name: 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid
Canonical SMILES: CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O
InChI: InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)
InChIKey: CGIGDMFJXJATDK-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3715
ChEBI ID: CHEBI:49662
CAS Number: 53-86-1
DrugBank ID: DB00328
TTD ID: D0R1RS
VARIDT ID: DR00267
INTEDE ID: DR0875
ACDINA ID: D00329

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase 2 (COX-2)	TTVKILB	PGH2_HUMAN	Modulator	[6]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[8]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[8]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[8]
UDP-glucuronosyltransferase 2B7 (UGT2B7)	DEB3CV1	UD2B7_HUMAN	Substrate	[9]
UDP-glucuronosyltransferase 1A9 (UGT1A9)	DE85D2P	UD19_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Rheumatoid arthritis

ICD Disease Classification

FA20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Prostaglandin G/H synthase 2 (COX-2)	DTT	PTGS2	7.93E-04	-0.29	-0.34
P-glycoprotein 1 (ABCB1)	DTP	P-GP	9.39E-02	1.07E-01	2.80E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	1.10E-01	-5.91E-02	-3.60E-01
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	2.40E-01	-3.31E-02	-1.97E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	1.90E-01	-9.81E-03	-5.96E-02

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Indomethacin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Sulfasalazine	DMICA9H	Moderate	Increased risk of nephrotoxicity by the combination of Indomethacin and Sulfasalazine.	Rheumatoid arthritis [FA20]	[65]
Dexamethasone	DMMWZET	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Indomethacin and Dexamethasone.	Rheumatoid arthritis [FA20]	[66]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Indomethacin and Leflunomide.	Rheumatoid arthritis [FA20]	[67]
-----------

Coadministration of a Drug Treating the Disease Different from Indomethacin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Indomethacin and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[68]
Repaglinide	DM5SXUV	Moderate	Increased risk of hypoglycemia by the combination of Indomethacin and Repaglinide.	Acute diabete complication [5A2Y]	[69]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Indomethacin and Glibenclamide.	Acute diabete complication [5A2Y]	[69]
Tolazamide	DMIHRNA	Moderate	Increased risk of hypoglycemia by the combination of Indomethacin and Tolazamide.	Acute diabete complication [5A2Y]	[69]
Nateglinide	DMLK2QH	Moderate	Increased risk of hypoglycemia by the combination of Indomethacin and Nateglinide.	Acute diabete complication [5A2Y]	[69]
Acetohexamide	DMR6N7H	Moderate	Increased risk of hypoglycemia by the combination of Indomethacin and Acetohexamide.	Acute diabete complication [5A2Y]	[69]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Indomethacin and Glipizide.	Acute diabete complication [5A2Y]	[69]
Thioguanine	DM7NKEV	Moderate	Increased risk of hepatotoxicity by the combination of Indomethacin and Thioguanine.	Acute myeloid leukaemia [2A60]	[70]
Arn-509	DMT81LZ	Moderate	Accelerated clearance of Indomethacin due to the transporter induction by Arn-509.	Acute myeloid leukaemia [2A60]	[71]
Inotersen	DMJ93CT	Major	Increased risk of bleeding by the combination of Indomethacin and Inotersen.	Amyloidosis [5D00]	[71]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Indomethacin and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[72]
Cilostazol	DMZMSCT	Moderate	Increased risk of bleeding by the combination of Indomethacin and Cilostazol.	Arterial occlusive disease [BD40]	[73]
Voriconazole	DMAOL2S	Moderate	Decreased metabolism of Indomethacin caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[68]
Budesonide	DMJIBAW	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Indomethacin and Budesonide.	Asthma [CA23]	[66]
Ofloxacin	DM0VQN3	Moderate	Additive CNS depression effects by the combination of Indomethacin and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[74]
Kanamycin	DM2DMPO	Moderate	Increased risk of nephrotoxicity by the combination of Indomethacin and Kanamycin.	Bacterial infection [1A00-1C4Z]	[75]
Ciprofloxacin XR	DM2NLS9	Moderate	Additive CNS depression effects by the combination of Indomethacin and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[74]
Amikacin	DM5PDRB	Moderate	Increased risk of nephrotoxicity by the combination of Indomethacin and Amikacin.	Bacterial infection [1A00-1C4Z]	[75]
Trovafloxacin	DM6AN32	Moderate	Additive CNS depression effects by the combination of Indomethacin and Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[74]
Sparfloxacin	DMB4HCT	Moderate	Additive CNS depression effects by the combination of Indomethacin and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[74]
Streptomycin	DME1LQN	Moderate	Increased risk of nephrotoxicity by the combination of Indomethacin and Streptomycin.	Bacterial infection [1A00-1C4Z]	[75]
Gemifloxacin	DMHT34O	Moderate	Additive CNS depression effects by the combination of Indomethacin and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[74]
Norfloxacin	DMIZ6W2	Moderate	Additive CNS depression effects by the combination of Indomethacin and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[74]
ABT-492	DMJFD2I	Moderate	Additive CNS depression effects by the combination of Indomethacin and ABT-492.	Bacterial infection [1A00-1C4Z]	[74]
Gentamicin	DMKINJO	Moderate	Increased risk of nephrotoxicity by the combination of Indomethacin and Gentamicin.	Bacterial infection [1A00-1C4Z]	[75]
Netilmicin	DMRD1QK	Moderate	Increased risk of nephrotoxicity by the combination of Indomethacin and Netilmicin.	Bacterial infection [1A00-1C4Z]	[75]
Levofloxacin	DMS60RB	Moderate	Additive CNS depression effects by the combination of Indomethacin and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[74]
Tobramycin	DMUI0CH	Moderate	Increased risk of nephrotoxicity by the combination of Indomethacin and Tobramycin.	Bacterial infection [1A00-1C4Z]	[75]
Lomefloxacin	DMVRH9C	Moderate	Additive CNS depression effects by the combination of Indomethacin and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[74]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of nephrotoxicity by the combination of Indomethacin and Etidronic acid.	Bone paget disease [FB85]	[76]
Risedronate	DM5FLTY	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Indomethacin and Risedronate.	Bone paget disease [FB85]	[76]
Alendronate	DMY2KX9	Moderate	Increased risk of nephrotoxicity by the combination of Indomethacin and Alendronate.	Bone paget disease [FB85]	[76]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Indomethacin and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[77]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Indomethacin caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[78]
Trastuzumab Emtansine	DMU1LXS	Moderate	Increased risk of bleeding by the combination of Indomethacin and Trastuzumab Emtansine.	Breast cancer [2C60-2C6Y]	[73]
Grepafloxacin	DMGLX0T	Moderate	Additive CNS depression effects by the combination of Indomethacin and Grepafloxacin.	Bronchitis [CA20]	[74]
Iodipamide	DMXIQYS	Major	Increased risk of nephrotoxicity by the combination of Indomethacin and Iodipamide.	Cholelithiasis [DC11]	[79]
Levomilnacipran	DMV26S8	Moderate	Increased risk of bleeding by the combination of Indomethacin and Levomilnacipran.	Chronic pain [MG30]	[80]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Indomethacin and Regorafenib.	Colorectal cancer [2B91]	[71]
Oxaliplatin	DMQNWRD	Moderate	Decreased renal excretion of Indomethacin caused by Oxaliplatin mediated nephrotoxicity.	Colorectal cancer [2B91]	[81]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Indomethacin and Drospirenone.	Contraceptive management [QA21]	[82]
Methoxyflurane	DML0RAE	Moderate	Increased risk of nephrotoxicity by the combination of Indomethacin and Methoxyflurane.	Corneal disease [9A76-9A78]	[71]
Ardeparin	DMYRX8B	Major	Increased risk of bleeding by the combination of Indomethacin and Ardeparin.	Coronary thrombosis [BA43]	[83]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Indomethacin caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[84]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Indomethacin caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[85]
Cidofovir	DMA13GD	Major	Increased risk of nephrotoxicity by the combination of Indomethacin and Cidofovir.	Cytomegaloviral disease [1D82]	[86]
MK-8228	DMOB58Q	Moderate	Increased metabolism of Indomethacin caused by MK-8228 mediated induction of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[87]
Danaparoid	DM6CLBN	Major	Increased risk of bleeding by the combination of Indomethacin and Danaparoid.	Deep vein thrombosis [BD71]	[83]
Rivaroxaban	DMQMBZ1	Major	Increased risk of bleeding by the combination of Indomethacin and Rivaroxaban.	Deep vein thrombosis [BD71]	[88]
Aprepitant	DM053KT	Moderate	Increased metabolism of Indomethacin caused by Aprepitant mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[89]
Sertraline	DM0FB1J	Moderate	Increased risk of bleeding by the combination of Indomethacin and Sertraline.	Depression [6A70-6A7Z]	[80]
Fluoxetine	DM3PD2C	Moderate	Increased risk of bleeding by the combination of Indomethacin and Fluoxetine.	Depression [6A70-6A7Z]	[80]
Vilazodone	DM4LECQ	Moderate	Increased risk of bleeding by the combination of Indomethacin and Vilazodone.	Depression [6A70-6A7Z]	[80]
Paroxetine	DM5PVQE	Moderate	Increased risk of bleeding by the combination of Indomethacin and Paroxetine.	Depression [6A70-6A7Z]	[80]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Indomethacin and Vortioxetine.	Depression [6A70-6A7Z]	[80]
Duloxetine	DM9BI7M	Moderate	Increased risk of bleeding by the combination of Indomethacin and Duloxetine.	Depression [6A70-6A7Z]	[80]
Milnacipran	DMBFE74	Moderate	Increased risk of bleeding by the combination of Indomethacin and Milnacipran.	Depression [6A70-6A7Z]	[80]
Escitalopram	DMFK9HG	Moderate	Increased risk of bleeding by the combination of Indomethacin and Escitalopram.	Depression [6A70-6A7Z]	[80]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of bleeding by the combination of Indomethacin and Desvenlafaxine.	Depression [6A70-6A7Z]	[80]
Clomipramine	DMINRKW	Moderate	Increased risk of bleeding by the combination of Indomethacin and Clomipramine.	Depression [6A70-6A7Z]	[80]
PMID28870136-Compound-49	DMTUC9E	Moderate	Increased risk of bleeding by the combination of Indomethacin and PMID28870136-Compound-49.	Discovery agent [N.A.]	[90]
Fenfluramine	DM0762O	Moderate	Increased risk of bleeding by the combination of Indomethacin and Fenfluramine.	Epilepsy/seizure [8A61-8A6Z]	[80]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Indomethacin and Cannabidiol.	Epileptic encephalopathy [8A62]	[71]
Ethacrynic acid	DM60QMR	Moderate	Antagonize the effect of Indomethacin when combined with Ethacrynic acid.	Essential hypertension [BA00]	[91]
Bendroflumethiazide	DM7EVLC	Moderate	Antagonize the effect of Indomethacin when combined with Bendroflumethiazide.	Essential hypertension [BA00]	[91]
Benzthiazide	DMQWZ0H	Moderate	Antagonize the effect of Indomethacin when combined with Benzthiazide.	Essential hypertension [BA00]	[91]
Tazemetostat	DMWP1BH	Moderate	Increased risk of bleeding by the combination of Indomethacin and Tazemetostat.	Follicular lymphoma [2A80]	[73]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Indomethacin and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[71]
Sulfinpyrazone	DMEV954	Moderate	Increased risk of bleeding by the combination of Indomethacin and Sulfinpyrazone.	Gout [FA25]	[73]
Spironolactone	DM2AQ5N	Moderate	Antagonize the effect of Indomethacin when combined with Spironolactone.	Heart failure [BD10-BD1Z]	[91]
Triamterene	DM2HU9I	Moderate	Antagonize the effect of Indomethacin when combined with Triamterene.	Heart failure [BD10-BD1Z]	[91]
Eplerenone	DMF0NQR	Moderate	Increased risk of hyperkalemia by the combination of Indomethacin and Eplerenone.	Heart failure [BD10-BD1Z]	[92]
Chlorothiazide	DMLHESP	Moderate	Antagonize the effect of Indomethacin when combined with Chlorothiazide.	Heart failure [BD10-BD1Z]	[91]
Furosemide	DMMQ8ZG	Moderate	Antagonize the effect of Indomethacin when combined with Furosemide.	Heart failure [BD10-BD1Z]	[91]
Amiloride	DMRTSGP	Moderate	Antagonize the effect of Indomethacin when combined with Amiloride.	Heart failure [BD10-BD1Z]	[91]
Bumetanide	DMRV7H0	Moderate	Antagonize the effect of Indomethacin when combined with Bumetanide.	Heart failure [BD10-BD1Z]	[91]
Hydroflumethiazide	DMVPUQI	Moderate	Antagonize the effect of Indomethacin when combined with Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[91]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Indomethacin caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[93]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Indomethacin and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[94]
Efavirenz	DMC0GSJ	Moderate	Increased risk of hepatotoxicity by the combination of Indomethacin and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[95]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Indomethacin caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[96]
Ritonavir	DMU764S	Minor	Increased metabolism of Indomethacin caused by Ritonavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[97]
Fenofibrate	DMFKXDY	Moderate	Decreased metabolism of Indomethacin caused by Fenofibrate mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[68]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Indomethacin and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[98]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Indomethacin and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[67]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Indomethacin and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[99]
Indapamide	DMGN1PW	Moderate	Antagonize the effect of Indomethacin when combined with Indapamide.	Hypertension [BA00-BA04]	[91]
Trichlormethiazide	DMHAQCO	Moderate	Antagonize the effect of Indomethacin when combined with Trichlormethiazide.	Hypertension [BA00-BA04]	[91]
Hydrochlorothiazide	DMUSZHD	Moderate	Antagonize the effect of Indomethacin when combined with Hydrochlorothiazide.	Hypertension [BA00-BA04]	[100]
Dipyridamole	DMXY30O	Moderate	Increased risk of bleeding by the combination of Indomethacin and Dipyridamole.	Hypertension [BA00-BA04]	[73]
Potassium chloride	DMMTAJC	Moderate	Increased risk of hyperkalemia by the combination of Indomethacin and Potassium chloride.	Hypo-kalaemia [5C77]	[101]
Fludrocortisone	DMUDIR8	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Indomethacin and Fludrocortisone.	Hypo-osmolality/hyponatraemia [5C72]	[66]
Balsalazide	DMO091F	Moderate	Increased risk of nephrotoxicity by the combination of Indomethacin and Balsalazide.	Indeterminate colitis [DD72]	[65]
Methotrexate	DM2TEOL	Major	Increased risk of nephrotoxicity by the combination of Indomethacin and Methotrexate.	Leukaemia [2A60-2B33]	[102]
Ibandronate	DM0QZBN	Moderate	Increased risk of nephrotoxicity by the combination of Indomethacin and Ibandronate.	Low bone mass disorder [FB83]	[71]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Indomethacin and Porfimer Sodium.	Lung cancer [2C25]	[103]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Indomethacin caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[68]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of bleeding by the combination of Indomethacin and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[104]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Indomethacin and Idelalisib.	Mature B-cell leukaemia [2A82]	[105]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Indomethacin and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[106]
Clofarabine	DMCVJ86	Moderate	Increased risk of nephrotoxicity by the combination of Indomethacin and Clofarabine.	Mature B-cell lymphoma [2A85]	[71]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Indomethacin and Ibrutinib.	Mature B-cell lymphoma [2A85]	[107]
Ponatinib	DMYGJQO	Major	Increased risk of bleeding by the combination of Indomethacin and Ponatinib.	Mature B-cell lymphoma [2A85]	[108]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Indomethacin caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[71]
Nitisinone	DMVS9WQ	Moderate	Decreased metabolism of Indomethacin caused by Nitisinone mediated inhibition of CYP450 enzyme.	Metabolism inborn error [5C50]	[90]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Indomethacin and Exjade.	Mineral absorption/transport disorder [5C64]	[109]
Zoledronate	DMIXC7G	Moderate	Increased risk of nephrotoxicity by the combination of Indomethacin and Zoledronate.	Mineral excesses [5B91]	[71]
Panobinostat	DM58WKG	Major	Increased risk of bleeding by the combination of Indomethacin and Panobinostat.	Multiple myeloma [2A83]	[68]
Deflazacort	DMV0RNS	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Indomethacin and Deflazacort.	Muscular dystrophy [8C70]	[66]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Indomethacin caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[110]
Dasatinib	DMJV2EK	Major	Increased risk of bleeding by the combination of Indomethacin and Dasatinib.	Myeloproliferative neoplasm [2A20]	[111]
Omacetaxine mepesuccinate	DMPU2WX	Major	Increased risk of bleeding by the combination of Indomethacin and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[112]
Prasugrel	DM7MT6E	Major	Increased risk of bleeding by the combination of Indomethacin and Prasugrel.	Myocardial infarction [BA41-BA43]	[71]
Vorapaxar	DMA16BR	Major	Increased risk of bleeding by the combination of Indomethacin and Vorapaxar.	Myocardial infarction [BA41-BA43]	[113]
Tirofiban	DMQG17S	Moderate	Increased risk of bleeding by the combination of Indomethacin and Tirofiban.	Myocardial infarction [BA41-BA43]	[114]
Sibutramine	DMFJTDI	Moderate	Increased risk of bleeding by the combination of Indomethacin and Sibutramine.	Obesity [5B80-5B81]	[80]
Dexfenfluramine	DMJ7YDS	Moderate	Increased risk of bleeding by the combination of Indomethacin and Dexfenfluramine.	Obesity [5B80-5B81]	[80]
Metolazone	DMB39LO	Moderate	Antagonize the effect of Indomethacin when combined with Metolazone.	Oedema [MG29]	[91]
Polythiazide	DMCH80F	Moderate	Antagonize the effect of Indomethacin when combined with Polythiazide.	Oedema [MG29]	[91]
Diclofenac	DMPIHLS	Moderate	Increased risk of hepatotoxicity by the combination of Indomethacin and Diclofenac.	Osteoarthritis [FA00-FA05]	[115]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Indomethacin caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[116]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Indomethacin and MK-4827.	Ovarian cancer [2C73]	[71]
Aspirin	DM672AH	Moderate	Increased risk of bleeding by the combination of Indomethacin and Aspirin.	Pain [MG30-MG3Z]	[117]
Prednisone	DM2HG4X	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Indomethacin and Prednisone.	Postoperative inflammation [1A00-CA43]	[66]
Betamethasone	DMAHJEF	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Indomethacin and Betamethasone.	Postoperative inflammation [1A00-CA43]	[66]
Hydrocortisone	DMGEMB7	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Indomethacin and Hydrocortisone.	Postoperative inflammation [1A00-CA43]	[66]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Indomethacin caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[118]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Indomethacin caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[119]
Treprostinil	DMTIQF3	Moderate	Increased risk of bleeding by the combination of Indomethacin and Treprostinil.	Pulmonary hypertension [BB01]	[120]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Indomethacin and Epoprostenol.	Pulmonary hypertension [BB01]	[120]
Everolimus	DM8X2EH	Major	Increased risk of nephrotoxicity by the combination of Indomethacin and Everolimus.	Renal cell carcinoma [2C90]	[121]
Temsirolimus	DMS104F	Major	Increased risk of nephrotoxicity by the combination of Indomethacin and Temsirolimus.	Renal cell carcinoma [2C90]	[121]
Gatifloxacin	DMSL679	Moderate	Additive CNS depression effects by the combination of Indomethacin and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[74]
Methylprednisolone	DM4BDON	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Indomethacin and Methylprednisolone.	Solid tumour/cancer [2A00-2F9Z]	[66]
Cyclophosphamide	DM4O2Z7	Minor	Increased risk of hyponatremia by the combination of Indomethacin and Cyclophosphamide.	Solid tumour/cancer [2A00-2F9Z]	[122]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Indomethacin and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[71]
Prednisolone	DMQ8FR2	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Indomethacin and Prednisolone.	Solid tumour/cancer [2A00-2F9Z]	[66]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Indomethacin and Pitolisant.	Somnolence [MG42]	[71]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Indomethacin and Naltrexone.	Substance abuse [6C40]	[123]
Caplacizumab	DMPUKA7	Moderate	Increased risk of bleeding by the combination of Indomethacin and Caplacizumab.	Thrombocytopenia [3B64]	[73]
Apixaban	DM89JLN	Major	Increased risk of bleeding by the combination of Indomethacin and Apixaban.	Thrombosis [DB61-GB90]	[71]
Cangrelor	DM8JRH0	Moderate	Increased risk of bleeding by the combination of Indomethacin and Cangrelor.	Thrombosis [DB61-GB90]	[73]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Indomethacin and Brilinta.	Thrombosis [DB61-GB90]	[71]
Cabozantinib	DMIYDT4	Major	Increased risk of bleeding by the combination of Indomethacin and Cabozantinib.	Thyroid cancer [2D10]	[124]
Sirolimus	DMGW1ID	Major	Increased risk of nephrotoxicity by the combination of Indomethacin and Sirolimus.	Transplant rejection [NE84]	[121]
Tacrolimus	DMZ7XNQ	Major	Increased risk of nephrotoxicity by the combination of Indomethacin and Tacrolimus.	Transplant rejection [NE84]	[121]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Indomethacin and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[69]
Chlorpropamide	DMPHZQE	Moderate	Increased risk of hypoglycemia by the combination of Indomethacin and Chlorpropamide.	Type 2 diabetes mellitus [5A11]	[69]
Olsalazine	DMZW9HA	Moderate	Increased risk of nephrotoxicity by the combination of Indomethacin and Olsalazine.	Ulcerative colitis [DD71]	[65]
Cinoxacin	DM4EWNS	Moderate	Additive CNS depression effects by the combination of Indomethacin and Cinoxacin.	Urinary tract infection [GC08]	[74]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Indomethacin and Plazomicin.	Urinary tract infection [GC08]	[75]
Nalidixic acid	DMRM0JV	Moderate	Additive CNS depression effects by the combination of Indomethacin and Nalidixic acid.	Urinary tract infection [GC08]	[74]
Enoxacin	DMYTE6L	Moderate	Additive CNS depression effects by the combination of Indomethacin and Enoxacin.	Urinary tract infection [GC08]	[74]
Triamcinolone	DM98IXF	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Indomethacin and Triamcinolone.	Vasomotor/allergic rhinitis [CA08]	[66]
Betrixaban	DM2C4RF	Major	Increased risk of bleeding by the combination of Indomethacin and Betrixaban.	Venous thromboembolism [BD72]	[125]
-----------


⏷ Show the Full List of 155 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 28	E00491	6097185	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Hydrazine yellow	E00409	164825	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Ammonia	E00007	222	Alkalizing agent
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Carboxymethylcellulose sodium	E00621	Not Available	Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium	E00625	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Lithol rubin BCA	E00607	135423095	Colorant
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Potassium hydroxide	E00233	14797	Alkalizing agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 34 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Indomethacin 25 mg capsule	25 mg	Oral Capsule	Oral
Indomethacin 50 mg capsule	50 mg	Oral Capsule	Oral
Indomethacin 20 mg capsule	20 mg	Oral Capsule	Oral
Indomethacin 75 mg capsule	75 mg	Extended Release Oral Capsule	Oral
Indomethacin 40 mg capsule	40 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	BDDCS applied to over 900 drugs
3	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7	Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1. Br J Cancer. 2007 Oct 22;97(8):1077-83.
8	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
9	Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur J Clin Pharmacol. 2007 Mar;63(3):289-96.
10	Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
11	Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
12	Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
13	UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
14	Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
15	Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
16	Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
17	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
18	Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
19	Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
20	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
21	Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
22	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
23	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
24	Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
25	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
26	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
27	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
28	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
29	High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
30	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
31	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
32	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
33	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
34	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
35	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
36	Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
37	Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
38	Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
39	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
40	Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
41	Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
42	Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
43	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
44	Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
45	Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
46	Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
47	The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
48	The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
49	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
50	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
51	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
52	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
53	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
54	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
55	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
56	Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
57	Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
58	Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
59	Pfizer. Product Development Pipeline. March 31 2009.
60	Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
61	Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
62	Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
63	Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
64	Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice. Eur Respir J. 2009 Jul;34(1):200-8.
65	Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
66	Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
67	EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
68	Cerner Multum, Inc. "Australian Product Information.".
69	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
70	Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
71	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
72	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
73	Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
74	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
75	Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
76	Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
77	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
78	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
79	Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
80	Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
81	Product Information. Eloxatin (oxaliplatin). Sanofi Winthrop Pharmaceuticals, New York, NY.
82	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
83	Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
84	Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
85	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
86	Product Information. Vistide (cidofovir). Gilead Sciences, Foster City, CA.
87	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
88	Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
89	Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
90	Canadian Pharmacists Association.
91	Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
92	Abdel-Haq B, Magagna A, Favilla S, Salvetti A "Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects." J Cardiovasc Pharmacol 18 (1991): s33-6. [PMID: 1725198]
93	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
94	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
95	Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
96	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
97	Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
98	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
99	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
100	McCarthy JT, Torres VE, Romero JC, et al "Acute intrinsic renal failure induced by indomethacin." Mayo Clin Proc 57 (1982): 289-96. [PMID: 6952058]
101	Product Information. Potassium Chloride ER (potassium chloride). Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.
102	Adams JD, Hunter GA "Drug interaction in psoriasis." Australas J Dermatol 17 (1976): 39-40. [PMID: 1022213]
103	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
104	Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
105	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
106	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
107	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
108	Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
109	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
110	Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
111	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
112	Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
113	Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
114	Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
115	Product Information. Solaraze (diclofenac topical). Doak Dermatologics Division, Fairfield, NJ.
116	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
117	Concomitant use of ibuprofen and aspirin. J Pain Palliat Care Pharmacother 21 (2007): 73-4. [PMID: 17844731]
118	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
119	Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
120	Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
121	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
122	Webberley MJ, Murray JA "Life-threatening acute hyponatraemia induced by low dose cyclophosphamide and indomethacin." Postgrad Med J 65 (1989): 950-2. [PMID: 2616440]
123	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
124	Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
125	Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.